|
|
KIF5B |
kinesin family member 5B |
- MHC class II antigen presentation
- Insulin processing
- RHO GTPases activate KTN1
- COPI-dependent Golgi-to-ER retrograde traffic
- Signaling by ALK fusions and activated point mutants
- Kinesins
|
|
|
|
|
KLF2 |
KLF transcription factor 2 |
|
|
|
|
|
KLF5 |
KLF transcription factor 5 |
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of granulopoiesis
|
|
|
|
|
LMO4 |
LIM domain only 4 |
|
|
|
|
|
LPCAT1 |
lysophosphatidylcholine acyltransferase 1 |
- Acyl chain remodelling of PC
- Acyl chain remodelling of PG
- Synthesis of PA
- Synthesis of PC
- Neutrophil degranulation
|
|
|
|
|
LRP6 |
LDL receptor related protein 6 |
- TCF dependent signaling in response to WNT
- Negative regulation of TCF-dependent signaling by WNT ligand antagonists
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Regulation of FZD by ubiquitination
- Signaling by RNF43 mutants
|
|
|
|
|
LUC7L2 |
LUC7 like 2, pre-mRNA splicing factor |
|
|
|
|
|
LYAR |
Ly1 antibody reactive |
|
|
|
|
|
MAP1B |
microtubule associated protein 1B |
|
|
|
|
|
MAP3K1 |
mitogen-activated protein kinase kinase kinase 1 |
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88 cascade initiated on plasma membrane
|
- AZD-8330
- Binimetinib
- Fostamatinib
|
|
|
|
MAP3K4 |
mitogen-activated protein kinase kinase kinase 4 |
|
|
|
|
|
MAP4 |
microtubule associated protein 4 |
|
- Paclitaxel
- Docetaxel
- Artenimol
|
|
|
|
MAPK1 |
mitogen-activated protein kinase 1 |
- phospho-PLA2 pathway
- RAF-independent MAPK1/3 activation
- MAPK1 (ERK2) activation
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Golgi Cisternae Pericentriolar Stack Reorganization
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- Recycling pathway of L1
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by MAPK mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Colforsin
- Purvalanol
- SB220025
- Seliciclib
- Perifosine
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- Hypothemycin
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- Turpentine
- Ulixertinib
|
|
|
|
MAPT |
microtubule associated protein tau |
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
- Flortaucipir F-18
|
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
|
|
|
MARK2 |
microtubule affinity regulating kinase 2 |
|
|
|
|
|
MASP1 |
MBL associated serine protease 1 |
- Lectin pathway of complement activation
- Initial triggering of complement
- Ficolins bind to repetitive carbohydrate structures on the target cell surface
- Scavenging by Class A Receptors
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
|
|
|
|
|
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
- Interleukin-4 and Interleukin-13 signaling
- Signaling by ALK fusions and activated point mutants
|
|
|
|
|
MDM2 |
MDM2 proto-oncogene |
- AKT phosphorylates targets in the cytosol
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- Trafficking of AMPA receptors
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
- Signaling by ALK fusions and activated point mutants
- Degradation of CDH1
- NPAS4 regulates expression of target genes
|
- Zinc
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Penile cancer
- Alveolar rhabdomyosarcoma
- Choriocarcinoma
- Osteosarcoma
- Glioma
|
|
|
MED24 |
mediator complex subunit 24 |
- PPARA activates gene expression
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- RSV-host interactions
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
|
|
|
MEG3 |
maternally expressed 3 |
|
|
|